Brandon Folkes Analyst PerformanceAnalyst at HC WainwrightBrandon Folkes is a stock analyst at HC Wainwright focused in the medical sector, covering 38 publicly traded companies. Over the past year, Brandon Folkes has issued 81 stock ratings, including strong buy and buy recommendations. While full access to Brandon Folkes' proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Brandon Folkes' coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings143 Last 9 YearsBuy Recommendations95.07% 135 Buy RatingsCompanies Covered38 Unique Companies Ratings Distribution142RatingsDistribution of strong buy, buy, hold, and sell ratings by Brandon Folkes.RatingPercentageCount Strong Buy0.7%1 ratings Buy94.4%134 ratings Hold4.9%6 ratings Sell0.0%0 ratingsOut of 142 total stock ratings issued by Brandon Folkes at HC Wainwright, the majority (94.4%) have been Buy recommendations, followed by 4.9% Hold and 0.7% Strong Buy.Best & Worst CallsBest Call0000.0%CNTBJun 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%HRTXJun 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ86.8% of companies on NASDAQ33 companiesNYSEAMERICAN5.3% of companies on NYSEAMERICAN2 companiesNYSE5.3% of companies on NYSE2 companiesTSE2.6% of companies on TSE1 companyBrandon Folkes, an analyst at HC Wainwright, currently covers 38 companies listed on NASDAQ, NYSEAMERICAN, NYSE and TSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical37 companies97.4%Manufacturing1 company2.6%Brandon Folkes of HC Wainwright specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE15 companies39.5%MED - DRUGS12 companies31.6%MED PRODUCTS4 companies10.5%MED INSTRUMENTS3 companies7.9%BIOTECHNOLOGY2 companies5.3%BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES1 company2.6%PHARMACEUTICAL PREPARATIONS1 company2.6% About Brandon FolkesBrandon Folkes has over a decade of experience in biopharma and biotechnology equity research. Prior to joining H.C. Wainwright, he served as Managing Director, Equity Research at Rodman & Renshaw and Managing Director, Equity Research at Cantor Fitzgerald. Prior to his tenure at Cantor, Mr. Folkes held equity research positions at Guggenheim Partners and CRT Capital. Before joining Wall Street, Mr. Folkes occupied roles at KPMG and PwC in the U.S., South Africa, and British Virgin Islands. Mr. Folkes holds degrees from Stellenbosch University and The University of South Africa; and earned the CFA and Chartered Accountancy designations.Follow on LinkedIn Brandon Folkes' Ratings History at HC Wainwright Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsOMEROmeros6/10/2026Reiterated Rating$9.97$40.00Buy$0.0000.00% ROITLPHTalphera6/5/2026Initiated Coverage$0.80$3.00Buy$0.0000.00% ROIHRTXHeron Therapeutics6/3/2026Lower Price Target$0.45$2.00Buy$0.0000.00% ROIRNTXRein Therapeutics6/1/2026Lower Price Target$1.11$8.00Buy$0.0000.00% ROISINTSintx Technologies5/20/2026Reiterated Rating$2.20$10.00Buy$0.0000.00% ROITRAWTraws Pharma5/20/2026Reiterated Rating$1.59$8.00Buy$0.0000.00% ROIOMEROmeros5/14/2026Reiterated Rating$14.38$40.00Buy$0.0000.00% ROIMNKDMannKind5/7/2026Boost Price Target$3.56$10.00Buy$0.0000.00% ROITRVITrevi Therapeutics5/6/2026Reiterated Rating$14.66$21.00Buy$0.0000.00% ROIEPRXEupraxia Pharmaceuticals5/4/2026Reiterated Rating$7.55$11.00Buy$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. EPRXEupraxia Pharmaceuticals4/22/2026Reiterated Rating$7.02$11.00Buy$0.0000.00% ROIACHVAchieve Life Sciences4/16/2026Reiterated Rating$3.55$12.00Buy$0.0000.00% ROISINTSintx Technologies4/13/2026Initiated Coverage$2.68$10.00Buy$0.0000.00% ROIRANIRani Therapeutics3/27/2026Reiterated Rating$1.08$11.00Buy$0.0000.00% ROIDERMJourney Medical3/26/2026Reiterated Rating$6.83$13.00Buy$0.0000.00% ROIACHVAchieve Life Sciences3/25/2026Reiterated Rating$2.90$12.00Buy$0.0000.00% ROICOLLCollegium Pharmaceutical3/20/2026Reiterated Rating$36.30$60.00Buy$0.0000.00% ROIPTHSPelthos Therapeutics3/19/2026Reiterated Rating$22.44$60.00Buy$0.0000.00% ROIEPRXEupraxia Pharmaceuticals3/17/2026Lower Price Target$7.39$11.00Buy$0.0000.00% ROISGMTSagimet Biosciences3/11/2026Reiterated Rating$5.65$29.00Buy$0.0000.00% ROITRVITrevi Therapeutics3/9/2026Reiterated Rating$11.80$21.00Buy$0.0000.00% ROIXERSXeris Biopharma3/2/2026Reiterated Rating$6.08$10.00Buy$0.0000.00% ROIMNKDMannKind2/25/2026Reiterated Rating$3.54$11.00Buy$0.0000.00% ROIPYPDPolyPid2/11/2026Reiterated Rating$4.59$13.00Buy$0.0000.00% ROIENTAEnanta Pharmaceuticals2/10/2026Reiterated Rating$13.83$20.00Buy$0.0000.00% ROICRDLCardiol Therapeutics2/10/2026Reiterated Rating$1.09$9.00Buy$0.0000.00% ROISGMTSagimet Biosciences2/3/2026Reiterated Rating$6.23$29.00Buy$0.0000.00% ROIMNKDMannKind1/26/2026Reiterated Rating$5.49$11.00Buy$0.0000.00% ROICRMDCorMedix1/23/2026Lower Price Target$7.44$13.00Buy$0.0000.00% ROIINDVIndivior1/12/2026Boost Price Target$35.44$48.00Buy$0.0000.00% ROICOLLCollegium Pharmaceutical1/9/2026Reiterated Rating$48.78$60.00Buy$0.0000.00% ROIENTAEnanta Pharmaceuticals1/9/2026Reiterated Rating$13.44$20.00Buy$0.0000.00% ROITRVITrevi Therapeutics1/9/2026Reiterated Rating$11.21$21.00Buy$0.0000.00% ROIRANIRani Therapeutics1/9/2026Reiterated Rating$1.39$11.00Buy$0.0000.00% ROIEPRXEupraxia Pharmaceuticals1/9/2026Reiterated Rating$8.59$12.00Buy$0.0000.00% ROIXERSXeris Biopharma1/9/2026Reiterated Rating$8.13$10.00Buy$0.0000.00% ROIHRTXHeron Therapeutics1/9/2026Reiterated Rating$1.50$6.00Buy$0.0000.00% ROIMNKDMannKind1/8/2026Reiterated Rating$6.16Buy$0.0000.00% ROIOMEROmeros1/8/2026Boost Price Target$14.09$40.00Buy$0.0000.00% ROIMISTMilestone Pharmaceuticals1/6/2026Reiterated Rating$2.06$8.00Buy$0.0000.00% ROIDOJ Admits It In Court—Your Cash Can Be Seized Without Warning (Ad)The Department of Justice recently argued in court that cash may not be legally your property - raising concerns about government authority to freeze or seize private accounts. Greece raided pensions. Cyprus drained bank accounts. Poland seized retirement funds. Priority Gold has put together a free Wealth Defense Guide for Americans looking to move assets beyond potential government reach.Download your free Wealth Defense Guide and review your options todayZVRAZevra Therapeutics12/30/2025Set Price Target$8.82$26.00$0.0000.00% ROIOMEROmeros12/24/2025Reiterated Rating$14.93Buy$0.0000.00% ROIMISTMilestone Pharmaceuticals12/15/2025Boost Price Target$2.55$8.00Buy$0.0000.00% ROITRAWTraws Pharma12/3/2025Initiated Coverage$2.16$8.00Buy$0.0000.00% ROITRAWTraws Pharma12/3/2025Initiated Coverage$2.11$8.00Buy$0.0000.00% ROICRDLCardiol Therapeutics12/1/2025Reiterated Rating$0.89$9.00Buy$0.0000.00% ROICRMDCorMedix11/13/2025Boost Price Target$11.42$18.00Buy$0.0000.00% ROIMNKDMannKind11/10/2025Reiterated Rating$5.44Buy$0.0000.00% ROIXERSXeris Biopharma11/7/2025Reiterated Rating$7.44$10.00Buy$0.0000.00% ROICOLLCollegium Pharmaceutical11/7/2025Boost Price Target$40.66$46.00Buy$0.0000.00% ROIINDVIndivior10/30/2025Boost Price Target$29.53$35.00Buy$0.0000.00% ROIRANIRani Therapeutics10/21/2025Reiterated Rating$2.25$11.00Buy$0.0000.00% ROIOMEROmeros10/15/2025Boost Price Target$10.20$20.00Buy$0.0000.00% ROIMNKDMannKind10/13/2025Reiterated Rating$4.88$11.00Buy$0.0000.00% ROIGNFTGENFIT9/24/2025Lower Price Target$3.65$7.00Buy$0.0000.00% ROIRNTXRein Therapeutics9/22/2025Initiated Coverage$1.21$10.00Buy$0.0000.00% ROIRNTXRein Therapeutics9/22/2025Initiated Coverage$1.18$10.00Buy$0.0000.00% ROIMNKDMannKind9/18/2025Reiterated Rating$5.39$11.00Buy$0.0000.00% ROIANIPANI Pharmaceuticals9/17/2025Boost Price Target$96.81$121.00Buy$0.0000.00% ROIMNKDMannKind9/2/2025Boost Price Target$5.72$11.00Buy$0.0000.00% ROIMNKDMannKind8/25/2025Reiterated Rating$4.05$9.00Buy$0.0000.00% ROIDERMJourney Medical8/25/2025Initiated Coverage$7.47$13.00Buy$0.0000.00% ROIVALNValneva8/25/2025Reiterated Rating$9.45$18.00Buy$0.0000.00% ROIACHVAchieve Life Sciences8/21/2025Initiated Coverage$2.58$12.00Buy$0.0000.00% ROIEPRXEupraxia Pharmaceuticals8/20/2025Reiterated Rating$5.38$12.00Buy$0.0000.00% ROIGNFTGENFIT8/19/2025Initiated Coverage$4.50$9.00Buy$0.0000.00% ROIVALNValneva8/19/2025Initiated Coverage$12.14$18.00Buy$0.0000.00% ROIPYPDPolyPid8/13/2025Reiterated Rating$3.52$13.00Buy$0.0000.00% ROICNTBConnect Biopharma8/13/2025Reiterated Rating$2.29$7.00Buy$0.0000.00% ROIXERSXeris Biopharma8/12/2025Initiated Coverage$7.20$10.00Buy$0.0000.00% ROICOLLCollegium Pharmaceutical8/11/2025Upgrade$34.93$44.00Strong-Buy$0.0000.00% ROIANIPANI Pharmaceuticals8/8/2025Reiterated Rating$81.49$93.00Buy$0.0000.00% ROICRMDCorMedix8/8/2025Lower Price Target$10.81$17.00Buy$0.0000.00% ROISGMTSagimet Biosciences8/7/2025Upgrade$9.17$29.00Buy$0.0000.00% ROIINDVIndivior8/6/2025Initiated Coverage$21.80$27.00Buy$0.0000.00% ROIENTAEnanta Pharmaceuticals7/28/2025Initiated Coverage$7.40$20.00Buy$0.0000.00% ROIMNKDMannKind7/16/2025Upgrade$3.85$9.00Buy$0.0000.00% ROIANIPANI Pharmaceuticals7/10/2025Initiated Coverage$65.31$84.00Buy$0.0000.00% ROIZVRAZevra Therapeutics7/2/2025Initiated Coverage$8.95$26.00Buy$0.0000.00% ROICRMDCorMedix6/30/2025Initiated Coverage$12.50$20.00Buy$0.0000.00% ROIEPRXEupraxia Pharmaceuticals6/26/2025Initiated Coverage$4.31$12.00Buy$0.0000.00% ROICNTBConnect Biopharma6/12/2025Initiated Coverage$0.82$7.00Buy$0.0000.00% ROIHRTXHeron Therapeutics6/9/2025Initiated Coverage$2.10$6.00Buy$0.0000.00% ROIMISTMilestone Pharmaceuticals6/5/2025Upgrade$1.65$5.00Buy$0.0000.00% ROICRDLCardiol Therapeutics6/2/2025Initiated Coverage$1.25$9.00Buy$0.0000.00% ROIPYPDPolyPid6/2/2025Upgrade$2.84$11.00Buy$0.0000.00% ROITRVITrevi Therapeutics5/28/2025Initiated Coverage$6.16$21.00Buy$00.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenMorgan StanleyHSBCUBS GroupCitigroupBarclaysWells Fargo & CompanyRoyal Bank Of CanadaJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerStifel Nicolaus Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
